DE60229233D1 - Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase - Google Patents

Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase

Info

Publication number
DE60229233D1
DE60229233D1 DE60229233T DE60229233T DE60229233D1 DE 60229233 D1 DE60229233 D1 DE 60229233D1 DE 60229233 T DE60229233 T DE 60229233T DE 60229233 T DE60229233 T DE 60229233T DE 60229233 D1 DE60229233 D1 DE 60229233D1
Authority
DE
Germany
Prior art keywords
prevention
stress
treatment
protein kinase
activated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229233T
Other languages
English (en)
Inventor
Lisa D Aimone
Robert L Hudkins
Mathew S Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of DE60229233D1 publication Critical patent/DE60229233D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60229233T 2001-05-16 2002-05-16 Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase Expired - Lifetime DE60229233D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29122701P 2001-05-16 2001-05-16
US10/146,680 US7018999B2 (en) 2001-05-16 2002-05-15 Methods for the treatment and prevention of pain
PCT/US2002/015667 WO2002092065A2 (en) 2001-05-16 2002-05-16 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60229233D1 true DE60229233D1 (de) 2008-11-20

Family

ID=26844179

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229233T Expired - Lifetime DE60229233D1 (de) 2001-05-16 2002-05-16 Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase

Country Status (13)

Country Link
US (1) US7018999B2 (de)
EP (1) EP1389100B1 (de)
JP (1) JP2004534751A (de)
AR (1) AR035971A1 (de)
AT (1) ATE410201T1 (de)
AU (1) AU2002342715A1 (de)
CA (1) CA2447091C (de)
DE (1) DE60229233D1 (de)
DK (1) DK1389100T3 (de)
ES (1) ES2314101T3 (de)
HK (1) HK1062806A1 (de)
MX (1) MXPA03010451A (de)
WO (1) WO2002092065A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
NZ592868A (en) 2008-11-19 2012-08-31 Cephalon Inc Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1381031A (en) 1920-01-19 1921-06-07 Thompson James Dumping-wagon
WO1988007045A1 (en) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
CA2123096A1 (en) 1991-11-08 1993-05-13 Beat J. Knusel Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621101A (en) 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2118414T3 (es) 1993-05-28 1998-09-16 Cephalon Inc Utilizacion de derivados del indolocarbazol para el tratamiento de la prostata.
US6514745B1 (en) 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5534426A (en) 1993-07-19 1996-07-09 The Regents Of The University Of California Oncoprotein protein kinase
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
AU1911095A (en) 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
BR9710693A (pt) 1996-06-25 2000-01-11 Cephalon Inc Uso de um derivado de k-252a para o tratamento do nervo central ou periférico e super produção de citoquinona.
WO1999033836A1 (en) 1997-12-31 1999-07-08 Cephalon, Inc. 3'-epimeric k-252a derivatives
ATE212552T1 (de) 1998-04-17 2002-02-15 Tufts College Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
GB9811624D0 (en) 1998-05-29 1998-07-29 Merck Sharp & Dohme Therapeutic use
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
HUP0103079A3 (en) 1998-08-26 2004-03-01 Cephalon Inc Modulating multiple lineage kinase proteins
ES2301255T3 (es) 1998-12-17 2008-06-16 F. Hoffmann-La Roche Ag 4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
AU760039B2 (en) 1998-12-17 2003-05-08 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of JNK protein kinases
TR200101747T2 (tr) 1998-12-17 2001-11-21 F.Hoffmann-La Roche Ag 4- ve 5-alkinil oksindoller ve 4- ve 5-alkeniloksindoller.
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
AU5316900A (en) 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
WO2001001986A1 (en) 1999-07-02 2001-01-11 Lipton Stuart A Method of reducing neuronal injury or apoptosis
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ｍｅｋ 억제제를 사용한 만성 통증의 치료 방법
PL366110A1 (en) 1999-08-13 2005-01-24 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
KR100835700B1 (ko) 1999-08-19 2008-06-09 시그널 파머슈티컬스 인크 Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를 함유하는 조성물
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
AU2002228911A1 (en) 2000-11-08 2002-05-21 The General Hospital Corporation Methods for inhibiting pain
WO2002046184A1 (en) 2000-12-05 2002-06-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
CA2447091A1 (en) 2002-11-21
EP1389100A2 (de) 2004-02-18
WO2002092065A2 (en) 2002-11-21
JP2004534751A (ja) 2004-11-18
AR035971A1 (es) 2004-07-28
US20030087899A1 (en) 2003-05-08
CA2447091C (en) 2012-03-27
US7018999B2 (en) 2006-03-28
ES2314101T3 (es) 2009-03-16
HK1062806A1 (en) 2004-11-26
MXPA03010451A (es) 2004-05-05
WO2002092065A3 (en) 2003-07-31
EP1389100B1 (de) 2008-10-08
AU2002342715A1 (en) 2002-11-25
ATE410201T1 (de) 2008-10-15
DK1389100T3 (da) 2008-12-08

Similar Documents

Publication Publication Date Title
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60143061D1 (de) Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE60221798D1 (de) Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60134009D1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60229233D1 (de) Neue verfahren zur behandlung und vorbeugung von schmerzmittel inhibitoren der stressaktivierten proteinkinase
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern
DE60203878D1 (de) Verfahren zur vorbeugung gegen und behandlung von unterleibsschmerzen und magen-darmerkrankungen
DE60023555D1 (de) Verfahren zur behandlung von gewebe
DE602004011275D1 (de) Zusammensetzungen und Verfahren zur Behandlung von Fettleibigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition